Biogen Inc. $BIIB Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lessened its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 22.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 83,120 shares of the biotechnology company’s stock after selling 23,801 shares during the quarter. Illinois Municipal Retirement Fund owned about 0.06% of Biogen worth $11,643,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of BIIB. Norges Bank purchased a new stake in Biogen in the second quarter valued at $284,358,000. Orion Porfolio Solutions LLC increased its position in shares of Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Biogen by 190.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after purchasing an additional 409,591 shares during the last quarter. AustralianSuper Pty Ltd boosted its position in shares of Biogen by 85.9% in the 2nd quarter. AustralianSuper Pty Ltd now owns 739,416 shares of the biotechnology company’s stock valued at $92,863,000 after purchasing an additional 341,719 shares during the period. Finally, Vanguard Group Inc. grew its stake in Biogen by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after buying an additional 257,812 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group reissued a “buy” rating on shares of Biogen in a report on Monday. HC Wainwright raised their price objective on shares of Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday. UBS Group started coverage on shares of Biogen in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price objective on the stock. Stifel Nicolaus increased their target price on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Morgan Stanley set a $190.00 price target on Biogen in a research report on Sunday. Twelve analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $205.84.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and raised FY‑2026 guidance — Biogen reported EPS and revenue above consensus and set FY‑2026 EPS guidance of $15.25–$16.25, which underpins improved earnings visibility and has been a major catalyst for analyst upgrades. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The subcutaneous formulation (lecanemab) received a priority review designation, which could expand commercial reach and margins if approved. This boosts upside to the Alzheimer’s franchise over the medium term. Article Title
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms lifted targets (Mizuho to $236, Citi, RBC, Canaccord and others raised targets), supporting further upside expectations and trading interest. Article Title
• Positive Sentiment: Institutional accumulation — Major holders (Vanguard, State Street, Geode, Norges Bank, Invesco) either added or maintain large stakes, indicating continued institutional conviction and providing bid support.
• Neutral Sentiment: Board chair transition — Caroline Dorsa is retiring and Dr. Maria C. Freire was elected chair. Governance change reduces uncertainty about succession but is unlikely to be an immediate earnings driver. Article Title
• Neutral Sentiment: Short‑interest data appears unreliable — Published short‑interest entries show zero shares / NaN changes and are internally inconsistent; there’s no clear sign of short‑covering driving today’s move.
• Negative Sentiment: Insider sale — Director/officer Priya Singhal sold 2,660 shares recently (filing shows sales around the $180–$200 range). Insider selling can raise short‑term concern about timing or valuation. Article Title
• Negative Sentiment: Ongoing franchise pressure and execution risk — Analysts and commentary note MS franchise pressures and execution risk around scaling Leqembi access/commercialization, which could cap upside if execution slips. Article Title

Biogen Stock Up 2.2%

Biogen stock opened at $195.50 on Friday. The firm has a market capitalization of $28.69 billion, a price-to-earnings ratio of 22.19, a price-to-earnings-growth ratio of 1.52 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The stock’s fifty day moving average is $177.92 and its two-hundred day moving average is $158.38.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the firm earned $3.44 EPS. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.